Neurology diagnoses and treats disorders of the nervous system, including the brain, spinal cord, and nerves, as well as thought and memory.
Send us all your questions or requests, and our expert team will assist you.
Translational neurology has ushered in the era of “theranostics,” a portmanteau of therapeutics and diagnostics. This approach involves developing a diagnostic test that identifies a specific molecular target, which is then paired with a therapy designed to hit that same target. It ensures that treatments are only given to patients who biologicaly express the disease mechanism.
This precision prevents the “trial and error” approach to prescribing. Instead of guessing if a drug will work, clinicians can use a theranostic agent to visualize the disease burden and predict the response. This is particularly prevalent in neuro-oncology and increasingly in neurodegenerative disorders.
Positron Emission Tomography (PET) scanning has been revolutionized by translational research. Scientists have developed specific radiotracers (ligands) that bind to proteins like amyloid and tau (in Alzheimer’s) or synaptic density markers. This allows clinicians to see the pathology in a living brain, which was previously only possible at autopsy.
These imaging tools are critical for early diagnosis. They can detect the accumulation of toxic proteins years before symptoms appear. In clinical trials, they are used to prove that a drug is actually removing the protein it is supposed to targeting, providing objective evidence of efficacy.
Translational advancements in MRI technology have led to the use of ultra high field scanners (7 Tesla and above). These powerful magnets allow for visualization of the brain at a microscopic resolution. Clinicians can now see cortical layers, microbleeds, and the specific subfields of the hippocampus.
This level of detail aids in the diagnosis of subtle conditions like focal cortical dysplasias in epilepsy or the specific iron accumulation patterns in Parkinsonian disorders. It transforms MRI from a macroscopic anatomical tool into a microscopic pathological probe.
One of the most transformative achievements in translational neurology is the development of blood based biomarkers for brain disease. Previously, assessing brain health required a painful lumbar puncture. Now, ultra sensitive assays (like SIMOA) can detect brain specific proteins like Neurofilament Light (NfL) or phosphorylated tau in a simple blood draw.
These “liquid biopsies” make it feasible to screen large populations for risk or to monitor a patient’s response to therapy frequent intervals. A drop in NfL levels, for example, indicates that a treatment is successfully reducing neuronal injury, providing immediate feedback to the clinician.
Next Generation Sequencing (NGS) has moved from the research lab to the diagnostic clinic. Rapid Whole Genome Sequencing (rWGS) can now diagnose rare pediatric neurological disorders in days, allowing for life saving interventions. The challenge now lies in the “translation” of this massive amount of data.
Translational bioinformaticians work to interpret genetic variants, distinguishing between harmless natural variations and disease causing mutations. This involves comparing a patient’s DNA against massive global databases to find patterns, turning raw data into a clinical diagnosis.
Send us all your questions or requests, and our expert team will assist you.
A PET ligand is a radioactive molecule designed to bind to a specific target in the brain, such as a protein clump, allowing it to be seen and measured on a PET scan.
We are getting very close; new blood tests can detect the proteins associated with Alzheimer’s with high accuracy, and they are currently being rolled out for use in specialist clinics.
A 7T MRI has a much stronger magnetic field than standard scanners, allowing it to take images with microscopic detail, revealing tiny lesions or changes that standard scans miss.
A liquid biopsy is a test done on a sample of blood (or other fluid) to look for cancer cells or pieces of DNA/protein from a tumor or organ, avoiding the need for a surgical biopsy.
We all have millions of genetic differences that make us unique, so it is very hard to tell which specific change is causing a disease and which is just a normal variation.
Your Comparison List (you must select at least 2 packages)
